Biomarkers for Traumatic Brain Injury provides a comprehensive overview on the selection and implementation of serum-based and saliva-based biomarkers for traumatic brain injury. The book presents an economic analysis for implementing TBI biomarkers into clinical practice. In addition, it discusses the analytical tools needed to implement TBI biomarkers, including specifications for testing instruments and interpretative software. Neurologists, emergency department physicians, intensivists, and clinical laboratorians will find this book a great resource from which to familiarize themselves with the issues and processes regarding TBI biomarkers.
Approximately 2 million people in the U.S. sustain a traumatic brain injury (TBI) each year with over 250,000 hospitalizations and 50,000 deaths. There has been a significant rise in interest in diagnosing mild concussions, particularly in the sports world. While imaging has been the gold standard, these procedures are costly and not always available. There is great potential in using serum-based biomarkers, hence the book seeks to enlighten readers on new possibilities.
- Offers strategies for the selection and implementation of traumatic brain injury biomarkers
- Discusses the importance of autoantibodies and post translational modifications for TBI
- Covers the analytical tools needed to implement TBI biomarkers, including the specifications for testing instruments and interpretative software
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Techn.
ISBN-13
978-0-12-816730-4 (9780128167304)
Schweitzer Klassifikation
Section I. INTRODUCTION1. Introduction-scope of the problem2. The need for traumatic brain injury markers3. Regulatory considerations for diagnostics and biomarkers of traumatic brain injury Section II. PATHOPHYSIOLOGY OF TBI4. Peripheral markers of TBI and blood-brain barrier disruption5. The role of autoimmunity after traumatic brain injury6. Traumatic brain injury: glial fibrillary acidic protein posttranslationalmodificationSECTION III. TBI BIOMARKERS IN MEDICAL PRACTICE7. Economics of traumatic brain injury biomarkers8. Electrophysiology monitoring9. Traumatic brain injury therapeuticsSECTION IV. CLASSICAL TBI BIOMARKERS10. S100 biomarkers in patients with traumatic brain injury11. Pathophysiology and clinical implementation of traumatic brain injury biomarkers: neuron-specific enolase12. Traumatic brain injury biomarkers glial fibrillary acidic protein/ubiquitin C-terminal hydrolase L113. Neurofilaments light chain/Neurofilaments heavy chain14. Tau protein, biomarker for traumatic brain injurySECTION V. NOVEL TBI BIOMARKERS15. Neurogranin16. Myelin basic protein in traumatic brain injurySECTION VI. ANALYTICAL TESTING CONSIDERATION17. Antibody selection, evaluation, and validation for analysis of traumatic brain injury biomarkers18. Sensitive immunoassay testing platforms19. Clinical mass spectrometry and its applications in traumatic brain injuries20. Surface plasmon resonance21. Point-of-care testing for concussion and traumatic brain injurySECTION VII. NON-BLOOD TBI BIOMARKER STRATEGY22. Clinical risk factors of traumatic brain injury23. Saliva biomarkers of traumatic brain injury24. Digital neurocognitive testing25. Electroencephalographic as a biomarker of concussion 26. Neuropsychological testing27. Outpatient risk stratification for traumatic brain injury28. Peptidomics and traumatic brain injury: biomarker utilities for a theragnostic approach29. Autoantibodies in central nervous system trauma: new frontiers for diagnosis and prognosis biomarkers
